WallStreetZenWallStreetZen

NASDAQ: MRNA
Moderna Inc Stock

$107.01-0.13 (-0.12%)
Updated Apr 11, 2024
MRNA Price
$107.01
Fair Value Price
$116.99
Market Cap
$40.89B
52 Week Low
$62.55
52 Week High
$163.24
P/E
-8.68x
P/B
2.95x
P/S
5.55x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.85B
Earnings
-$4.71B
Gross Margin
31.5%
Operating Margin
-57.56%
Profit Margin
-68.8%
Debt to Equity
0.33
Operating Cash Flow
-$3B
Beta
0.58
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A

MRNA Overview

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MRNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MRNA ($107.01) is undervalued by 8.53% relative to our estimate of its Fair Value price of $116.99 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MRNA ($107.01) is not significantly undervalued (8.53%) relative to our estimate of its Fair Value price of $116.99 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MRNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MRNA due diligence checks available for Premium users.

Be the first to know about important MRNA news, forecast changes, insider trades & much more!

MRNA News

Valuation

MRNA fair value

Fair Value of MRNA stock based on Discounted Cash Flow (DCF)
Price
$107.01
Fair Value
$116.99
Undervalued by
8.53%
MRNA ($107.01) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MRNA ($107.01) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MRNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

MRNA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-8.68x
Industry
14.34x
Market
43.63x

MRNA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.95x
Industry
6.04x
MRNA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MRNA's financial health

Profit margin

Revenue
$2.8B
Net Income
$217.0M
Profit Margin
7.7%
MRNA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MRNA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$18.4B
Liabilities
$4.6B
Debt to equity
0.33
MRNA's short-term assets ($10.33B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MRNA's short-term assets ($10.33B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MRNA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MRNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$622.0M
Investing
-$538.0M
Financing
-$109.0M
MRNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

MRNA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
MRNA$40.89B-0.12%-8.68x2.95x
ARGX$22.47B-0.82%-67.69x5.05x
BNTX$20.68B-1.85%20.68x0.94x
GMAB$19.65B-0.70%30.66x4.27x
ALNY$19.16B-0.21%-43.21x-86.81x

Moderna Stock FAQ

What is Moderna's quote symbol?

(NASDAQ: MRNA) Moderna trades on the NASDAQ under the ticker symbol MRNA. Moderna stock quotes can also be displayed as NASDAQ: MRNA.

If you're new to stock investing, here's how to buy Moderna stock.

What is the 52 week high and low for Moderna (NASDAQ: MRNA)?

(NASDAQ: MRNA) Moderna's 52-week high was $163.24, and its 52-week low was $62.55. It is currently -34.45% from its 52-week high and 71.08% from its 52-week low.

How much is Moderna stock worth today?

(NASDAQ: MRNA) Moderna currently has 382,073,208 outstanding shares. With Moderna stock trading at $107.01 per share, the total value of Moderna stock (market capitalization) is $40.89B.

Moderna stock was originally listed at a price of $18.60 in Dec 7, 2018. If you had invested in Moderna stock at $18.60, your return over the last 5 years would have been 475.32%, for an annualized return of 41.9% (not including any dividends or dividend reinvestments).

How much is Moderna's stock price per share?

(NASDAQ: MRNA) Moderna stock price per share is $107.01 today (as of Apr 11, 2024).

What is Moderna's Market Cap?

(NASDAQ: MRNA) Moderna's market cap is $40.89B, as of Apr 13, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Moderna's market cap is calculated by multiplying MRNA's current stock price of $107.01 by MRNA's total outstanding shares of 382,073,208.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.